Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

March 28, 2024

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

March 22, 2024

Damian Green, MD, will join Sylvester Comprehensive Cancer Center this spring to lead its transplantation and cellular therapy services.

March 22, 2024

Shanta Dhar, PhD, FRSC, discusses the significance of being named a fellow of the National Academy of Inventors for her research in prostate cancer.

March 21, 2024

Jay Spiegel, MD, discusses advancing cellular therapies and challenges in gynecologic cancer treatment.

March 15, 2024

Some head and neck cancers may respond to the drug olaparib or the combination of olaparib with decitabine.

March 04, 2024

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

March 04, 2024

Patients with chronic lymphocytic leukemia and related blood cancers are often prescribed targeted drugs called BTK inhibitors.

February 29, 2024

The blood cancer expert comes to Sylvester Comprehensive Cancer Center after leading the discovery and testing of several immunotherapy approaches.

February 27, 2024

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

February 15, 2024

Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.

February 14, 2024

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

February 06, 2024

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

February 03, 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

February 02, 2024

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

January 10, 2024

Marijo Bilusic, MD, PhD, discusses key considerations and unanswered questions regarding the use of PARP inhibitors in patients with prostate cancer.

January 06, 2024

Shanta Dhar, PhD, assistant director of Technology and Innovation at Sylvester Comprehensive Cancer Center, has been named a fellow of the National Academy of Inventors.

December 19, 2023

Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.

December 15, 2023

Marijo Bilusic, MD, PhD, highlights key insights about renal cell carcinoma that were presented at the meeting covering considerations on sequencing TKIs, the need for further research to elucidate novel therapies, and the importance of offering clinical trials to all patients with genitourinary malignancies.

December 04, 2023

Macarena de la Fuente, MD, becomes the first Hispanic elected and will represent neurology on the multidisciplinary board.

December 01, 2023

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.